PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule

Radiother Oncol. 2014 Feb;110(2):355-61. doi: 10.1016/j.radonc.2013.12.014. Epub 2014 Feb 4.

Abstract

Background and purpose: PLK1-inhibitors are emerging as new potential anticancer agents. It is therefore important to explore the combined effects of PLK1-inhibitors with conventional therapies. Based on the functional roles of PLK1 in both mitosis and the G2 checkpoint, we hypothesized that the treatment schedule might influence the combined effects of PLK1-inhibiton and radiation.

Materials and methods: Human osteosarcoma U2OS and colorectal cancer HT29 and SW620 cells were treated with the PLK1-inhibitor BI2536 before or after X-ray irradiation (0-6 Gy). Clonogenic assays, flow cytometry, immunofluorescence and mCherry-53BP1 time-lapse imaging were used to assay cell survival, cell cycle progression and DNA damage repair.

Results: Treatment with the PLK1-inhibitor for 24h before radiation caused cells to accumulate in G2/M and resulted in increased radiosensitivity. In contrast, the cytotoxic effects of the two treatments were less-than-additive when cells were treated with the PLK1-inhibitor for 24h after radiation. This resistance was associated with a prolonged G2 checkpoint causing enhanced repair of the radiation-induced damage and decreased BI2536-mediated mitotic damage.

Conclusions: PLK1-inhibitors need to be administrated several hours before radiation to achieve radiosensitization. If PLK1-inhibitors are given after radiation, cell killing is reduced due to the prolonged G2 checkpoint.

Keywords: Cancer; Combined treatment; DNA damage; G2 checkpoint; Ionizing radiation; Mitosis; PLK1-inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / genetics
  • Bone Neoplasms / pathology
  • Bone Neoplasms / radiotherapy
  • Cell Cycle / drug effects
  • Cell Cycle / radiation effects
  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Chemoradiotherapy
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / radiotherapy
  • DNA Damage
  • DNA Repair
  • Flow Cytometry
  • HT29 Cells
  • Humans
  • Osteosarcoma / drug therapy
  • Osteosarcoma / genetics
  • Osteosarcoma / pathology
  • Osteosarcoma / radiotherapy
  • Polo-Like Kinase 1
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Pteridines / pharmacology*
  • Radiation Tolerance / drug effects

Substances

  • BI 2536
  • Cell Cycle Proteins
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Pteridines
  • Protein Serine-Threonine Kinases